Shares of Athersys ATHX increased in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were unchanged 0.00% over the past year to ($0.10), which were in line with the estimate of ($0.10).
Revenue of $0 decreased by 100.00% year over year, which missed the estimate of $40,000.
Looking Ahead
Athersys hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Aug 09, 2021
Time: 04:30 PM
Price Action
Company's 52-week high was at $3.03
Company's 52-week low was at $1.35
Price action over last quarter: down 1.29%
Company Profile
Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is a unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
